Aldeyra Therapeutics, Inc. (ALDX) Stock Price

ALDXStock
$1.4974.66%52W
Market Cap$89.58M
P/E
PEG Ratio
Div yield
Beta1.19

ALDX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-83.43%
Price vs S&P 500 (4W)-4.48%
VGM Score22.75

ALDX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.08-$0.09-16.13%(-$0.01)
Q1 2026-$0.12-$0.06+50.00%(+$0.06)
Q4 2025-$0.14-$0.10+31.03%(+$0.04)
Q3 2025-$0.16-$0.13+17.46%(+$0.03)
Q2 2025-$0.19-$0.16+14.67%(+$0.03)

ALDX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.25
4.25
4.25

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ALDXAldeyra Therapeutics, Inc.
D$1.49
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a clinical-stage biotechnology company developing medicines for immune-mediated and metabolic diseases. Its lead candidate, Reproxalap, is in late-stage development for dry eye disease and allergic conjunctivitis. The company's pipeline also includes candidates targeting retinal diseases, autoimmune conditions, and cancer.